Company presentations
Anaveon AG
Anaveon AG is a clinical stage company developing immunotherapies for diseases with high unmet medical need.
Pipeline: ANV110: Bispecific targeting inflammation and fibrosis (Ph1); ANV200: mAb to eliminate alloreactive and autoreactive T/B cells (pre-CMC); ANV600: bispecific IL-2 agonist to activate pre-exhausted T cells (Ph1) and ANV700: IL-21-based bispecific to localize immune stimulation in the TME (pre-CMC).
Anaveon is actively Actively pursuing strategic partnerships.
Date, time and room information
May 6, 13:45 - 14:00, room Montreal
Category
Clinical stage development company
Speaker information
| Name | Position | Institution |
|---|---|---|
| Andreas Katopodis | CEO | Anaveon |
